Dr. Reddy’s Announces the Launch of Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg in the U.S. Market
July 20 2018 - 2:13AM
Business Wire
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:
RDY, along with its subsidiaries together referred to as “Dr.
Reddy’s”) today announced the launch of Esomeprazole Magnesium
Delayed-Release Capsules USP, 20 mg, an over-the-counter (OTC)
therapeutic equivalent generic version of Nexium® 24HR Capsules in
the United States market as approved by the U.S. Food and Drug
Administration (USFDA).
Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg, is
an OTC proton pump inhibitor used to treat frequent heartburn
occurring two or more days a week in adults*.
"This launch continues to demonstrate our deep R&D and
manufacturing capabilities to bring newer store-brand OTC
medications to the market,” says Milan Kalawadia, Vice President
and Head, US OTC and Speciality Rx businesses, Dr. Reddy’s
Laboratories. “We look forward to collaborating with our customers
to provide high-quality, affordable alternatives to consumers.”
The combined market of Nexium® 24HR Capsules and private label
OTC Esomeprazole Magnesium products had U.S. sales of approximately
$311 million for the most recent twelve months ending in May 2018
according to IRI†.
Dr. Reddy’s Esomeprazole Magnesium Delayed-Release Capsules USP,
20 mg is available in 14 count bottles sold in cartons of 1, 2, or
3 bottles each. Each bottle contains a complete 14-day course of
treatment. Use only as directed.
*May take 1 to 4 days for full effect. †IRI Latest 52 wks.
period ending May 2018Nexium® is a registered trademark of
AstraZeneca AB.
OTC-002-0618
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE:
500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical
company, committed to providing affordable and innovative medicines
for healthier lives. Through its three businesses - Pharmaceutical
Services & Active Ingredients, Global Generics and Proprietary
Products – Dr. Reddy’s offers a portfolio of products and services
including APIs, custom pharmaceutical services, generics,
biosimilars and differentiated formulations. Our major therapeutic
areas of focus are gastrointestinal, cardiovascular, diabetology,
oncology, pain management and dermatology. Dr. Reddy’s operates in
markets across the globe. Our major markets include – USA, India,
Russia & CIS countries, and Europe. For more information, log
on to: www.drreddys.com.
Disclaimer: This press release may include statements of
future expectations and other forward-looking statements that are
based on the management’s current views and assumptions and involve
known or unknown risks and uncertainties that could cause actual
results, performance or events to differ materially from those
expressed or implied in such statements. In addition to statements
which are forward-looking by reason of context, the words "may",
"will", "should", "expects", "plans", "intends", "anticipates",
"believes", "estimates", "predicts", "potential", or "continue" and
similar expressions identify forward-looking statements. Actual
results, performance or events may differ materially from those in
such statements due to without limitation, (i) general economic
conditions such as performance of financial markets, credit
defaults , currency exchange rates , interest rates , persistency
levels and frequency / severity of insured loss events (ii)
mortality and morbidity levels and trends, (iii) changing levels of
competition and general competitive factors, (iv) changes in laws
and regulations and in the policies of central banks and/or
governments, (v) the impact of acquisitions or reorganization ,
including related integration issues.
The company assumes no obligation to update any information
contained herein.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180719006015/en/
Dr. Reddy’s Laboratories Ltd.INVESTOR
RELATIONSSAUNAK SAVLA,
+91-40-49002135saunaks@drreddys.comorMEDIA RELATIONSCALVIN
PRINTER, +91-40-49002121calvinprinter@drreddys.com
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Apr 2023 to Apr 2024